We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Hyloris Reports Full Year Results for 2023 & Provides Business Outlook Hyloris Reports Full Year Results for 2023 & Provides Business Outlook Total revenue and other income amounted...
Communication at the request of the FSMA on the transactions with Qliniq Communication at the request of the FSMA on the transactions with Qliniq Revision of 2022 and half-year of 2023 (HY...
Hyloris Annonce ses Résultats Financiers Annuels le 14 mars 2024 Liège, Belgique – le 8 mars 2024, 07:00 heures CET - Information non réglementée - Hyloris Pharmaceuticals SA (Euronext...
Liège, Belgium – 08 February 2024, 07:00 AM CET – Non-regulated information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet...
Hyloris Annonce le Lancement de Maxigesic® IV aux Etats-Unis ainsi que son Approbation au Canada Hyloris Annonce le Lancement de Maxigesic® IV aux Etats-Unis ainsi que son Approbation au...
Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada Maxigesic® IV, a Potent Non-opioid...
Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures Innovative oral care solution aims to...
Hyloris et Purna Female Healthcare Annoncent des Résultats Positifs de leur Essai Clinique de Phase 2 chez des Patientes atteintes de Candidose Vulvovaginale Aiguë (CVV) Hyloris et Purna...
Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS) Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS) Equal Partnership...
Hyloris Elargit son Portefeuille de Produits avec un Nouveau Produit Candidat pour le Lichen Scléreux Vulvaire (LSV) Co-Partenariat avec AFT Pharmaceuticals pour le Développement d'un Film...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.15 | -1.25 | 12 | 12.2 | 11.7 | 8492 | 11.92998893 | DE |
4 | 0.7 | 6.27802690583 | 11.15 | 12.75 | 11.1 | 14229 | 12.09651329 | DE |
12 | -1.4 | -10.5660377358 | 13.25 | 13.3 | 11 | 11183 | 12.09333102 | DE |
26 | -0.55 | -4.43548387097 | 12.4 | 13.3 | 10.6 | 10379 | 12.28817988 | DE |
52 | -0.95 | -7.421875 | 12.8 | 14.1 | 10.6 | 7589 | 12.16861681 | DE |
156 | -0.9 | -7.05882352941 | 12.75 | 19.1 | 10.6 | 6428 | 13.80720754 | DE |
260 | 1.1 | 10.2325581395 | 10.75 | 19.1 | 8.8 | 8265 | 12.84966512 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions